marked.bio

Company

Compass Therapeutics

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 3 trials shown

  1. A Phase 1 Study of the Safety and Tolerability of CTX-10726

    Recruiting Phase 1 Compass Therapeutics Started 2026Primary completion 2028-04 NCT07419841

    CTX-10726

    Patients with MSI- high or deficient DNA mismatch repair (dMMR) tumors who have progressed after a minimum of 2 d…

    MSI-H / dMMRGastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)

  2. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    Recruiting Phase 1 Compass Therapeutics Started 2024Primary completion 2026-12 NCT06150664

    CTX-8371

    Patients with HER2-low tumors (HER2 IHC 1+ or 2+/ISH negative) need to have received fam-trastuzumab deruxtecan …

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma